Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Mavorixafor is an effective and selective antagonist of <a href="/target/CXCR" style="display: inline; color: #c13a36">CXCR</a>4, with an IC50 value of 13 nM against <a href="/target/CXCR" style="display: inline; color: #c13a36">CXCR</a>4 125I-SDF binding. Mavorixafor inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells (IC50 = 1 nM) and PBMCs (IC50 = 9 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 113.00 | |
5 mg | In stock | $ 163.00 | |
10 mg | In stock | $ 232.00 | |
25 mg | In stock | $ 417.00 | |
50 mg | In stock | $ 677.00 | |
100 mg | In stock | $ 1,217.00 | |
200 mg | In stock | $ 2,117.00 | |
500 mg | In stock | $ 3,987.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 316.00 |
Description | Mavorixafor is an effective and selective antagonist of CXCR4, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Mavorixafor inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells (IC50 = 1 nM) and PBMCs (IC50 = 9 nM). |
Targets&IC50 | HIV-1 (NL4.3 strain):1 nM (in MT-4 cells), HIV-1 (NL4.3 strain):3 nM (in MT-4 cells), HIV-1 (NL4.3 strain):9 nM (in PBMCs), 125I-SDF-CXCR4:13 nM |
In vitro | Mavorixafor (6.6 µM) significantly decreases the anchorage-dependent growth, migration, and matrigel invasion of the B88-SDF-1 cells [1]. Mavorixafor shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2) [2]. |
In vivo | AMD-070 (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss [1]. |
Cell Research | Cells are seeded on a 96-well plate at 5 × 10^3 cells/well in DMEM containing 10% FCS. Twenty-four hours later, the cells are treated with or without 2 µM AMD3100 or 6.6 µM AMD-070. After 24 or 48 h, the number of cells is quantified by an assay using MTT [2]. |
Animal Research | BALB/c nude mice are maintained under pathogen-free conditions. The experiments are initiated when the mice are 8 weeks of age. Briefly, the cells are inoculated into the blood vessels of nude mice (1× 10^6). These mice are sacrificed at day 49. The presence or absence of distant metastases is confirmed by hematoxylin and eosin (H&E) staining. For experimental chemotherapy, the mice are treated by the daily oral administration of 0.2 mL of saline for a vehicle or the same volume of AMD-070 (2 mg/kg) [2]. |
Synonyms | AMD-070 |
Molecular Weight | 349.47 |
Formula | C21H27N5 |
CAS No. | 558447-26-0 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ethanol: 44 mg/mL (125.9 mM)
H2O: 7 mg/mL (20.03 mM), warming
DMSO: 17 mg/mL (48.64 mM)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mavorixafor 558447-26-0 Autophagy GPCR/G Protein Immunology/Inflammation CXCR AMD 070 AMD-070 Human immunodeficiency virus AMD070 HIV inhibit CXC chemokine receptors Inhibitor inhibitor